(ANRO) Alto Neuroscience - Ratings and Ratios

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock •

ANRO: Depression, Schizophrenia, PTSD, Antidepressants, Cognitive Impairment

Alto Neuroscience, Inc. (NYSE:ANRO) is a clinical-stage biopharmaceutical company focused on developing innovative treatments for mental health disorders. Its pipeline includes ALTO-100, currently in Phase 2b trials for major depressive disorder (MDD) and Phase 2a for post-traumatic stress disorder (PTSD). ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist, is in Phase 2b trials for MDD. The company also develops ALTO-101, a novel phosphodiesterase 4 inhibitor in Phase 1 for cognitive impairment in schizophrenia, and ALTO-203, a histamine H3 receptor inverse agonist in Phase 1 for MDD with high anhedonia. Additionally, ALTO-202, an NMDA receptor GluN2B subunit antagonist, is in Phase 1 for MDD. Alto Neuroscience also focuses on pharmacodynamically synergistic combinations and a biomarker platform to identify patient-specific treatment responses. Founded in 2019, the company is based in Los Altos, California.

From a technical standpoint, ANROs stock shows a declining trend, with SMA20 at 3.25, SMA50 at 3.90, and SMA200 at 8.47, indicating long-term downward momentum. Average volume of 410,875 shares suggests moderate liquidity, with an ATR of 0.31 reflecting limited price volatility. The stock last traded at 3.38.

Fundamentally, Alto Neuroscience has a market cap of $86.03M, with a P/B ratio of 0.51, indicating undervaluation relative to book value. The company reports a return on equity (RoE) of -34.81%, reflecting ongoing losses typical of early-stage biotech firms. With no P/E or P/S ratios due to lack of earnings or sales, the stock is speculative, driven by clinical trial outcomes and pipeline progression.

Over the next 3 months, ANRO is expected to remain under pressure, with SMA20 and SMA50 trending downward. Support may emerge near $3.00, while resistance could form at $4.00. ATR suggests limited volatility, with price movements likely confined to a narrow range. Fundamental catalysts, such as clinical trial updates, could drive short-term price movements.

Additional Sources for ANRO Stock

ANRO Stock Overview

Market Cap in USD 96m
Sector Healthcare
Industry Biotechnology
GiC Sub-Industry Pharmaceuticals
IPO / Inception 2024-02-02

ANRO Stock Ratings

Growth 5y -49.9%
Fundamental -
Dividend 0.0%
Rel. Strength Industry -77.7
Analysts 4.71/5
Fair Price Momentum 2.06 USD
Fair Price DCF -

ANRO Dividends

No Dividends Paid

ANRO Growth Ratios

Growth Correlation 3m -56.7%
Growth Correlation 12m -83.5%
Growth Correlation 5y -85.6%
CAGR 5y -76.76%
CAGR/Max DD 5y -0.88
Sharpe Ratio 12m 0.44
Alpha -89.87
Beta 1.96
Volatility 90.49%
Current Volume 242.6k
Average Volume 20d 238.8k
What is the price of ANRO stocks?
As of March 14, 2025, the stock is trading at USD 3.16 with a total of 242,600 shares traded.
Over the past week, the price has changed by -20.00%, over one month by -3.07%, over three months by -17.49% and over the past year by -77.75%.
Is Alto Neuroscience a good stock to buy?
Probably not. Based on ValueRay Analyses, Alto Neuroscience (NYSE:ANRO) is currently (March 2025) not a good stock to buy. It has a ValueRay Growth Rating of -49.87 and therefor a somwhat technical negative rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of ANRO as of March 2025 is 2.06. This means that ANRO is currently overvalued and has a potential downside of -34.81%.
Is ANRO a buy, sell or hold?
Alto Neuroscience has received a consensus analysts rating of 4.71. Therefor, it is recommend to buy ANRO.
  • Strong Buy: 6
  • Buy: 0
  • Hold: 1
  • Sell: 0
  • Strong Sell: 0
What are the forecast for ANRO stock price target?
According to ValueRays Forecast Model, ANRO Alto Neuroscience will be worth about 2.4 in March 2026. The stock is currently trading at 3.16. This means that the stock has a potential downside of -24.37%.
Issuer Forecast Upside
Wallstreet Target Price 12.7 302.5%
Analysts Target Price 12.7 302.5%
ValueRay Target Price 2.4 -24.4%